<DOC>
	<DOCNO>NCT00895310</DOCNO>
	<brief_summary>The purpose study test safety ketoconazole well work chemotherapy use . Ketoconazole low dos use fungal infection however yet approve Food Drug Administration use prostate cancer . Ketoconazole use many year high dos prostate cancer , study look use low dose ketoconazole someone receive chemotherapy . Ketoconazole work halt production steroid body , include testosterone , think work directly prostate cancer cell publish lab study .</brief_summary>
	<brief_title>Use Low Dose Ketoconazole Prostate Cancer That Does Not Respond Hormone Therapy Prior Chemotherapy</brief_title>
	<detailed_description>The aim study research response low dose ketoconazole hormone refractory prostate cancer ( HRPC ) patient already undergone chemotherapy part prostate cancer treatment . The hypothesis study HRPC patient previously treat chemotherapy demonstrate objective PSA response rate low dose ketoconazole , comparable historical response rate report chemotherapy-na√Øve patient . This single arm trial , participant give ketoconazole 200mg TID , along hydrocortisone give 20mg morning , 10mg night daily . Each cycle consist 28 day . The subject 's study participation continue subject experience disease progression , unacceptable toxicity , withdraws consent study dy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Patients must histologically cytologically proven prostate cancer Gleason score available interpretable . Patients must prostate cancer deem hormone refractory , progression measurable evaluable disease rise PSA . Patients must &gt; 18 year old Patients must receive least one prior chemotherapy regimen &gt; 3 week prior initiation study patient must recover side effect therapy Patients must ECOG status 03 Patients must normal organ marrow function , determine within 14 day registration . Patients must surgically medically castrate . If method castration LHRH agonist ( leuprolide goserelin ) , patient must willing continue use LHRH agonist . Patients must serum total testosterone level &lt; 50 ng/dl If patient treat nonsteroidal antiandrogens ( flutamide , bicalutamide nilutamide ) hormonal treatment ( megace steroid ) , patient must stop agent least 28 day prior enrollment flutamide , megace steroid least 42 day prior enrollment bicalutamide nilutamide ; patient must demonstrate progression disease since agent suspend . Patients condition impairs ability swallow medication orally Patients unable give inform consent Patients receive ketoconazole treatment prostate cancer past Patients active malignancy past 3 year except nonmelanoma skin cancer Patients may receive investigational agent Patients know hypersensitivity ketoconazole Patients may take certain medication , include terbinafine , astemizole , triazolam , statin ( except pravastatin fluvastatin ) acid suppressive agent ( antacid , H2 blocker , PPI ) ketoconazole , patient medication must agree discontinue medication consider alternative therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PSA</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Hormone Refractory</keyword>
	<keyword>Chemotherapy Regimen</keyword>
</DOC>